Literature DB >> 22843758

Small cell carcinoma of gastro-oesophageal junction with remarkable response to chemo-radiotherapy.

Mototsugu Matsunaga1, Keisuke Miwa, Tsuyoshi Noguchi, Yasutsuna Sasaki.   

Abstract

Small cell carcinoma of the gastrointestinal tract is rare, and no effective strategy has yet been established. On the basis of regimens reportedly effective for small cell lung cancer, we performed chemotherapy with cisplatin plus etoposide in combination with radiotherapy to relieve obstruction, in a patient with small cell carcinoma of the gastro-oesophageal junction. Chemotherapy was switched to carboplatin plus etoposide due to renal toxicity. No distant metastases were detected and lesion spread was limited. A complete response, with no evidence of recurrence to date, was achieved. Curative resection was suggested but refused by the patient. He has been closely followed up in our outpatient clinic for more than a year and has shown no evidence of recurrence since the completion of treatment. Although cisplatin plus etoposide is a standard chemotherapy regimen for small cell carcinoma, carboplatin plus etoposide may be effective in cases in which cisplatin is contraindicated due to renal toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843758      PMCID: PMC4543306          DOI: 10.1136/bcr-2012-006361

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach.

Authors:  Baruch Brenner; Laura H Tang; Jinruh Shia; David S Klimstra; David P Kelsen
Journal:  Semin Oncol       Date:  2007-02       Impact factor: 4.929

2.  Tumor spread and outcome of treatment in primary esophageal small cell carcinoma.

Authors:  T Nishimaki; T Suzuki; S Nakagawa; K Watanabe; K Aizawa; K Hatakeyama
Journal:  J Surg Oncol       Date:  1997-02       Impact factor: 3.454

3.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

Authors:  Kazumasa Noda; Yutaka Nishiwaki; Masaaki Kawahara; Shunichi Negoro; Takahiko Sugiura; Akira Yokoyama; Masahiro Fukuoka; Kiyoshi Mori; Koshiro Watanabe; Tomohide Tamura; Seiichiro Yamamoto; Nagahiro Saijo
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

4.  Long-term survival after resection for small cell carcinoma of the esophagus.

Authors:  S Yachida; K Matsushita; H Usuki; H Wanibuchi; T Maeba; H Maeta
Journal:  Ann Thorac Surg       Date:  2001-08       Impact factor: 4.330

5.  Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.

Authors:  S Kudoh; Y Fujiwara; Y Takada; H Yamamoto; A Kinoshita; Y Ariyoshi; K Furuse; M Fukuoka
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

6.  Small cell carcinoma of the esophagus.

Authors:  S Y Law; M Fok; K Y Lam; S L Loke; L T Ma; J Wong
Journal:  Cancer       Date:  1994-06-15       Impact factor: 6.860

Review 7.  Small-cell carcinomas of the gastrointestinal tract: a review.

Authors:  Baruch Brenner; Laura H Tang; David S Klimstra; David P Kelsen
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

8.  Primary small cell carcinoma of the esophagus: report of a case.

Authors:  I Muto; T Nishimaki; K Aizawa; T Suzuki; O Tanaka; K Hatakeyama
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  Esophageal carcinoma. The unusual variants.

Authors:  M D Lieberman; D Franceschi; B Marsan; M Burt
Journal:  J Thorac Cardiovasc Surg       Date:  1994-12       Impact factor: 5.209

10.  Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.

Authors:  H Okamoto; K Watanabe; H Kunikane; A Yokoyama; S Kudoh; T Asakawa; T Shibata; H Kunitoh; T Tamura; N Saijo
Journal:  Br J Cancer       Date:  2007-06-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.